清肠止痢汤和艾灸辅助治疗溃疡性结肠炎的效果及对炎症因子的影响

doi:10.12092/j.issn.1009-2501.2019.02.013

摘要/Abstract

摘要：

目的: 探究清肠止痢汤和艾灸辅助美沙拉嗪治疗溃疡性结肠炎的疗效及对炎症因子的影响。方法: 选取温州市中医院2016年7月至2018年3月间诊断及治疗的溃疡性结肠炎患者110例，采用随机数表法分为联合治疗组（55例）和对照组（55例），对照组采用美沙拉嗪治疗，0.8 g，3次/d，口服，联合治疗组在此基础上予以清肠止痢汤，100 mL，1次/d，口服，及艾灸治疗，30 min/d，疗程均为2周。比较2组患者治疗前后的临床疗效、中医证候积分、改良Mayo活动指数、Baron内镜分级评分、炎症因子［肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-8（IL-8）］，以及药物不良反应情况。结果: 联合治疗组的临床治疗总有效率明显高于对照组（χ2=6.111，P=0.013），治疗前两组中医证候积分无明显差异（P＞0.05），治疗后两组均显著下降（P＜0.05），其中联合治疗组的证候积分显著小于对照组（P＜0.05）；治疗前两组患者的Mayo活动指数与Baron内镜分级评分均无明显差异（P＞0.05）。治疗后两组患者的上述指标均显著下降（P＜0.05），其中联合治疗组显著小于对照组（t=-17.407，-13.671；P=0.000，P=0.000）；治疗前两组TNF-α、IL-6、IL-8水平无显著差异（P＞0.05）；治疗后两组上述指标均显著下降（P＜0.05），其中联合治疗组治疗后各炎症因子水平显著低于对照组（t=-19.611，-7.391，-5.404；P=0.000，P=0.000，P=0.000）；两组不良反应总发生率无显著差异（7.27% vs.14.55%；χ2=0.842，P=0.359）。结论:清肠止痢汤和艾灸辅助美沙拉嗪治疗溃疡性结肠炎的疗效肯定，且能更好控制肠道黏膜炎症及体内炎症因子水平。

关键词: 清肠止痢汤, 艾灸, 溃疡性结肠炎, 炎症因子

Abstract:

AIM:To expolre the effect of Qingchang zhili soup and moxibustion on ulcerative colitis and inflammatory factors. METHODS:From July 2016 to May 2017,a total of 110 patients with ulcerative colitis in our hospital were randomly divided into combined treatment group(55 cases) and control group(55 cases),the control group was treated with methalazine,0.8 g,3 times/d, and the combined treatment group received extra Qingchang zhili soup,100 mL,1 time/d and moxibustion,30 min/d,the course of treatment were 2 weeks.The curative effect,TCM syndrome scoring,the Improve Mayo activity index,Baron endoscopy grading,inflammatory cytokines including tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-8(IL-8) before and after treatment were compared,the adverse reactions during the treatment were also recorded and compared. RESULTS:The total effective rate of the combined treatment group was significantly higher than that of the control group（χ2=6.111，P=0.013）.There was no significant difference in TCM syndrome score between the two groups before treatment（P＞0.05）,both groups decreased significantly after treatment（P＜0.05）,the syndrome score of the combined treatment group was significantly lower than control group（P＜0.05）.There was no significant difference in Improve Mayo activity index and Baron endoscopy grading between the two groups before treatment（P＞0.05）,they were significantly reduced in both groups after treatment（P＜0.05）,the scores in combined treatment group were significantly lower than those of the control group（t=-17.407，-13.671；P=0.000，P=0.000）.There was no significant difference in levels of TNF-α, IL-6, IL-8 between the two groups before treatment（P＞0.05）, they were significantly reduced in both groups after treatment（P＜0.05）,the levels in combined treatment group were significantly lower than the control group（t=-19.611，-7.391，-5.404；P=0.000，P=0.000，P=0.000）.There was no significant difference in incidence of adverse reactions between the two groups（7.27% vs.14.55%；χ2=0.842，P=0.359）.CONCLUSION:The efficacy of Qingchang zhili soup and moxibustion in the treatment of ulcerative colitis is positive;it can better control the intestinal mucosal inflammation and inflammatory factor levels.

Key words: Qingchang zhili soup, moxibustion, ulcerative colitis, inflammatory factor

中图分类号:

郑伟伟，王嘉嘉. 清肠止痢汤和艾灸辅助治疗溃疡性结肠炎的效果及对炎症因子的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 198-204.

ZHENG Weiwei, WANG Jiajia. Effects of Qingchang zhili soup and moxibustion on ulcerative colitis and inflammatory factors[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 198-204.

参考文献

［1］Bürger M, Schmidt C, Teich N, Stallmach A. Medical therapy of active ulcerative colitis［J］. Viszeralmedizin, 2015,31(4):236-245.
［2］Cawthorpe D, Davidson M. Temporal comorbidity of mental disorder and ulcerative colitis［J］. Perm J, 2015,19(1):52.
［3］易蕊, 常娟, 刘晓艳, 等. TNF-α、IL-6及IL-8在不同程度溃疡性结肠炎患者血清中的表达及意义［J］. 现代生物医学进展, 2015,15(14):2641-2644.
［4］Daniel, Langenberg. Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal ［J］ ? World J Gastrointest Pharmacol Ther, 2015,6(4):137-144.
［5］李开学, 曾理, 舒晴. 益生菌联合美沙拉嗪治疗轻、中度活动期溃疡性结肠炎的效果及安全性［J］.中国医学创新,2017,14(8):56-59.
［6］中华医学会消化病学分会炎症性肠病协作组. 对我国炎症性肠病诊断治疗规范的共识意见(2007年,济南)［J］.中华消化杂志,2007,27(8):545-550.
［7］张声生, 沈洪, 郑凯, 等. 溃疡性结肠炎中医诊疗专家共识意见(2017)［J］.中华中医药杂志,2017,32(8):3585-3589.
［8］郑筱萸. 中药新药临床研究指导原则［M］. 北京:中国医药科技出版社,2002:290-292.
［9］国家中医药管理局. 中医病证诊断疗效标准［M］:南京大学出版社,1994.
［10］常泰, 王浩源, 李民, 等. 评价溃疡性结肠炎的CECT表现与临床、肠镜之间的相关性［J］. 医学影像学杂志, 2017,27(7):1311-1313.
［11］马旭园, 代志峰, 王慧超, 等. 溃疡性结肠炎患者肠道菌群的变化及其与IL-23/IL-17轴的关系［J］. 中国病理生理杂志, 2018,34(5):884-892.
［12］Deroche TC, Xiao SY, Liu X. Histological evaluation in ulcerative colitis［J］. Gastroenterol Rep (Oxf), 2014 , 2(3):178-192.
［13］魏中山. 美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的临床疗效与安全性比较［J］. 临床合理用药杂志, 2016,9(2):51-52.
［14］王迪, 高建平, 李兰珍. 温肾健脾法治疗溃疡性结肠炎研究概况［J］.中国中医药信息杂志,2016,23(5):127-130.
［15］赵婕. 溃疡性结肠炎中医辨证论治文献研究［J］. 亚太传统医药, 2014,10(2):35-38.
［16］Marchioni BR, Kane S. Current approaches to the management of new-onset ulcerative colitis［J］. Clin Exp Gastroenterol, 2014,7:111-132.
［17］Paine ER. Colonoscopic evaluation in ulcerative colitis［J］. Gastroenterol Rep (Oxf), 2014, 2(3):161-168.
［18］Qin Q, Liu YN, Jin X, et al. Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model［J］. World J Gastroenterol, 2018,24(28):3130-3144.
［19］Sato S, Chiba T, Nakamura S, et al.Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis［J］. J Gastroenterol Hepatol, 2015,30(10):1467-1472.
［20］王晓梅, 黄艳, 王圆圆, 等. 艾灸对溃疡性结肠炎大鼠结肠TLR4和TNF-α蛋白及其mRNA表达影响的研究［J］. 世界科学技术-中医药现代化, 2016,18(3):374-380.
［21］李颖, 魏新智. 白芍不同炮制品的镇痛、镇静、抗炎作用比较［J］.辽宁中医药大学学报,2016,18(4):39-41.
［22］姜琛璐, 汤承, 骞宇, 等. 黄芪多糖免疫调节作用研究进展［J］.食品科学,2013,34(11):327-332.
［23］游昕, 熊大国, 郭志斌, 等. 茯苓多种化学成分及药理作用的研究进展［J］. 安徽农业科学, 2015,4(02):106-109.
［24］Kruis W, Kardalinos V, Eisenbach T, et al. Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence［J］. Aliment Pharmacol Ther, 2017,46(3):282.

[1]	李阳, 潘维忠, 张晓录, 于翠翠. 回收式自体血回输对行剖宫产术患者免疫功能及炎症反应的影响[J]. 中国临床药理学与治疗学, 2023, 28(5): 514-524.
[2]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[3]	李军民, 牛恒立, 谢明全, 苏金龙. 山楂黄酮抗动脉粥样硬化及降血脂作用机制研究[J]. 中国临床药理学与治疗学, 2023, 28(3): 276-282.
[4]	黄玉荣, 张红强, 游蓉丽, 贾颖, 王艳, 樊杰, 王颖莉. 青黛散外用凝胶对特异性皮炎小鼠的改善作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 19-28.
[5]	高家荣, 施苗苗, 陈浩, 姜辉, 秦秀娟. 芪藤消浊颗粒介导miR-339-5p对慢性肾小球肾炎大鼠炎症指标的影响[J]. 中国临床药理学与治疗学, 2022, 27(4): 457-465.
[6]	王瑞杰, 王亮, 徐丹, 周淼淼, 李纪明. PCSK9抑制剂对冠心病患者血脂及炎症因子的影响[J]. 中国临床药理学与治疗学, 2022, 27(4): 409-417.
[7]	何秀娟, 马慧可, 刘青武, 陈佳, 林燕, 李萍. 细胞因子在创面修复中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(5): 579-585.
[8]	杨慧芳, 罗颖, 赵莉. 右美托咪定对脓毒症大鼠肾功能及血清炎症因子的影响[J]. 中国临床药理学与治疗学, 2020, 25(8): 857-861.
[9]	茹彩旺, 袁天明, 杨兵芬, 吴福根, 林应荣, 莫妙军. 亚胺培南-西司他丁钠联合免疫球蛋白对婴儿脓毒症并发弥散性血管内凝血的疗效[J]. 中国临床药理学与治疗学, 2020, 25(5): 559-565.
[10]	赵玮, 吴悠扬, 林丛, 黄时伟, 陈皓, 姜文兵. 紫檀芪对急性心肌梗死大鼠心肌功能、心肌纤维化和炎症反应的作用及对Notch1/eIF3a信号通路的影响[J]. 中国临床药理学与治疗学, 2020, 25(5): 498-504.
[11]	皮治兵，杨学志，彭宇，张钧凯，张磊，林海. 低剂量巴氯芬辅助治疗对三叉神经痛患者的疗效及对炎症因子、氧化应激反应的影响[J]. 中国临床药理学与治疗学, 2020, 25(3): 317-322.
[12]	王艳红, 蒲君峰, 李红玲, 冯铁新. 锰超氧化物歧化酶模拟物对三硝基苯磺酸诱导溃疡性结肠炎大鼠的保护作用及机制研究[J]. 中国临床药理学与治疗学, 2020, 25(10): 1081-1087.
[13]	姜莉，李宇宁，庞立宏，张兴道，王芳. N-乙酰半胱氨酸联合肺表面活性物质对新生儿重症胎粪吸入综合征的疗效及其对胎儿炎症因子及氧合功能的影响[J]. 中国临床药理学与治疗学, 2020, 25(1): 81-86.
[14]	谢方英，陈浙丽，高月蓝. 益气养阴生肌方对复发性口腔溃疡大鼠的治疗作用及其对黏膜炎症因子和机体免疫功能的影响[J]. 中国临床药理学与治疗学, 2019, 24(1): 20-26.
[15]	黄立佳，黄杨，孔劲松，郑鑫，宫小康，阮建伟，王海宝. 阿托伐他汀钙经STAT1-caspase-3信号轴抑制膝骨关节炎大鼠关节软骨退变的研究[J]. 中国临床药理学与治疗学, 2018, 23(7): 743-748.